The Pharmabiotics Conference 2026 is not just another scientific meeting. Now celebrating its 10th edition, it has become the Conference of D&R (Development & Regulation): where Discovery is translated into Development, guided by Direction from Regulation, built on Dialogue across disciplines and with authorities, and driven by the Disruption that microbiome science brings to health, food systems, and sustainability.

What sets this conference apart is its focus on regulatory case studies. With regulatory frameworks still under construction, researchers and developers will share their journeys, real-world experiences that become practical case studies for the entire community. These insights are not only about presenting science, but about turning individual challenges into collective knowledge.

This unique positioning is clearly reflected in the conference programme, which features sessions on biomarkers and diagnostics, One Health applications, regulatory assessment, and advances in clinical data and emerging technologies. Each theme illustrates how scientific discovery meets regulatory direction to shape the next decade of microbiome innovation.

Backed by the Pharmabiotic Research Institute (PRI), an independent EU non-profit and recognized stakeholder, the conference ensures that the dialogue between science and regulation carries real weight with regulators, industry, and academia alike.